-
A total of 52 articles were identified after an initial search, 20 of which were duplicate articles (Figure 1). Twenty-three articles were further excluded because of duplicate sample use (5), animal or function studies (4), studies on other diseases (8), and review or comments (6) (Figure 1). From the above, we identified nine articles, which were included in the SUMO4 M55V analysis (Table 1). One study was further excluded because of significant disequilibrium in the Hardy-Weinberg equilibrium test. Finally, eight articles including 10 case-control studies, with a total of 2932 cases and 2679 controls, were included in this meta-analysis. The study quality is summarized in Table 2. The quality of the studies included in this meta-analysis was acceptable (at least 5 points).
Table 1. Characteristics of Case-control Studies Included in Meta-analysis
Study Year Ethnicity/Region Population Group Subject Size Diagnosis Genotyping Method P-value for HWE Noso S[15] 2007 Western area Japanese T2DM 355 ADA Taqman SNP genotyping assay 0.690 Control 398 0.291 Shimada T[20] 2009 Wakayama Japanese T2DM 423 WHO Taqman SNP genotyping assay 0.716 Control 436 0.094 Shimada T[20] 2009 Tokyo Japanese T2DM 451 WHO 0.408 Control 469 0.378 Ji Z[17] 2010 Hunan Chinese T2DM 427 WHO PCR-RFLP 0.830 Control 281 0.079 Li B[21] 2011 Yunan Chinese T2DM 232 WHO PCR-RFLP 0.260 Control 102 0.126 Lin HY[16] 2007 Taiwan Chinese T2DM 574 NA PCR-RFLP 0.193 Control 323 0.466 Fallah S[22] 2010 Tehran Irani T2DM 50 NA PCR-RFLP 0.493 Control 50 0.998 Hu RT[23] 2009 Va Chinese T2DM 96 WHO PCR-RFLP 0.487 Control 104 0.673 Hu RT[23] 2009 Lalu Chinese T2DM 54 WHO PCR-RFLP 0.088 Control 234 0.817 Pu LM[18] 2012 Beijing Chinese T2DM 270 WHO PCR-HRM 1.92 × 10-5 Control 282 0.086 Note. ADA: American Diabetes Association. WHO: World Health Organization. PCR-RFLP: Polymerase Chain Reaction-Restriction Fragment Length Polymorphism restriction fragment length polymorphism. NA: not reported in the paper. Table 2. Assessment of Case-control Studies Using Newcastle-Ottawa Scale for Evaluating Methodological Quality
Study Case Definition Representativeness of the Case Selection of Controls Definition of Controls Comparability Ascertainment of Exposure Same Method of Ascertainment for Cases and Controls Non-Response Rate Noso S 2007[15] √ √ √ √ √ √ √ √ Shimada T 2009[20] √ √ √ √ √ √ √ Shimada T 2009[20] √ √ √ √ √ √ √ Lin HY 2007[16] √ √ √ √ √ √ √ Ji Z 2010[17] √ √ √ √ √ √ Li B 2011[21] √ √ √ √ √ √ √ Hu RT 2009[23] √ √ √ √ √ √ √ Hu RT 2009[23] √ √ √ √ √ √ √ Pu LM 2012[18] √ √ √ √ √ √ √ √ Fallah S 2010[12] √ √ √ √ √ √ -
Figure 2 presents the forest plot of the association between the SUMO4 M55V polymorphism (also named G163A in SUMO4, or rs237025) and T2DM in each studies and the meta analysis. The significant association between the SUMO4 M55V polymorphism and susceptibility to T2DM was observed in the dominant model (GG + GA versus AA: OR = 1.21, 95% CI = 1.05-1.40, P = 0.009), recessive model (GG versus GA + AA: OR = 1.29, 95% CI = 1.06-1.56, P = 0.010), homozygous model (GG versus AA: OR = 1.41, 95% CI = 1.15-1.71, P = 0.001), and additive model (G versus A: OR = 1.18, 95% CI = 1.08-1.29, P= 0.001), and marginally significant in the heterozygous model (GA versus AA: OR = 1.16, 95%CI = 0.98-1.36, P = 0.080).
Figure 2. Forest plots of meta-analysis of the association between SUMO4 M55V polymorphisms and T2DM in a dominant model (A), recessive model (B), homozygous model (C), heterozygous model (D), and additive model (E).
No significant subgroup differences were observed (P ranged from 0.52 to 0.56 in all five genetic models). Subgroup analysis showed significant associations between the SUMO4 M55V polymorphism and susceptibility to T2DM in the Chinese population under all but the heterozygous model (GA versus AA: OR = 1.12, 95% CI = 0.86-1.44, P = 0.090) and marginally significant associations in the Japanese population (P ranged from 0.13 to 0.40 in all five genetic models).
-
Funnel plot asymmetry was evaluated by Egger's regression test. If the line passed through the origin, it would indicate the absence of publication bias. The funnel plots and Egger's linear regression test are shown in Figure 3. No publication biases were detected under the five genetic models (all P > 0.05).
Figure 3. Publication biases indicated by the funnel plots. Figure A, dominant model, P = 0.655 and 0.550 in Begg's and Egger's test, respectively. Figure B, recessive model, P = 0.245 and 0.063 in Begg's and Egger's test, respectively. Figure C, homozygous model, P = 0.074 and 0.131 in Begg's and Egger's test, respectively. Figure D, heterozygous model, P = 0.655 and 0.237 in Begg's and Egger's test, respectively. Figure E, additive model, P = 0.788 and 0.866 in Begg's and Egger's test, respectively.
A sensitivity analysis was conducted to explore the sources of heterogeneity, and the results showed that no single study affected the pooled OR and CIs in a qualitative manner.
doi: 10.3967/bes2017.038
Association between the SUMO4 M55V Polymorphism and Susceptibility to Type 2 Diabetes Mellitus: A Meta-analysis
-
Abstract:
Objective The aim of this study is to determine whether the SUMO4 M55V polymorphism is associated with susceptibility to type 2 diabetes mellitus (T2DM). Methods A meta-analysis was performed to detect the potential association of the SUMO4 M55V polymorphism and susceptibility to T2DM under dominant, recessive, co-dominant (homogeneous and heterogeneous), and additive models. Results A total of eight articles including 10 case-control studies, with a total of 2932 cases and 2679 controls, were included in this meta-analysis. The significant association between the SUMO4 M55V polymorphism and susceptibility to T2DM was observed in the dominant model (GG + GA versus AA: OR = 1.21, 95% CI = 1.05-1.40, P= 0.009), recessive model (GG versus GA + AA: OR = 1.29, 95% CI = 1.07-1.356, P= 0.010), homozygous model (GG versus AA: OR = 1.41, 95% CI = 1.06-1.56, P= 0.001), and additive model (G versus A: OR = 1.18, 95% CI = 1.08-1.29, P=0.001), and marginally significant in the heterozygous model (GA versus AA: OR = 1.16, 95% CI = 0.98-1.36, P= 0.080). In subgroup analyses, significant associations were observed in the Chinese population under four genetic models excluding the heterozygous model, whereas no statistically significant associations were observed in the Japanese population under each of the five genetic models. Conclusion The meta-analysis demonstrated that the G allele of the SUMO4 M55V polymorphism could be a susceptible risk locus to T2DM, mainly in the Chinese population, while the association in other ethnic population needs to be further validated in studies with relatively large samples. -
Key words:
- SUMO4 /
- Type 2 diabetes mellitus (T2DM) /
- Polymorphisms /
- Meta-analysis
注释:1) CONFLICT OF INTEREST: 2) AUTHORS CONTRIBUTIONS: -
Figure 3. Publication biases indicated by the funnel plots. Figure A, dominant model, P = 0.655 and 0.550 in Begg's and Egger's test, respectively. Figure B, recessive model, P = 0.245 and 0.063 in Begg's and Egger's test, respectively. Figure C, homozygous model, P = 0.074 and 0.131 in Begg's and Egger's test, respectively. Figure D, heterozygous model, P = 0.655 and 0.237 in Begg's and Egger's test, respectively. Figure E, additive model, P = 0.788 and 0.866 in Begg's and Egger's test, respectively.
Table 1. Characteristics of Case-control Studies Included in Meta-analysis
Study Year Ethnicity/Region Population Group Subject Size Diagnosis Genotyping Method P-value for HWE Noso S[15] 2007 Western area Japanese T2DM 355 ADA Taqman SNP genotyping assay 0.690 Control 398 0.291 Shimada T[20] 2009 Wakayama Japanese T2DM 423 WHO Taqman SNP genotyping assay 0.716 Control 436 0.094 Shimada T[20] 2009 Tokyo Japanese T2DM 451 WHO 0.408 Control 469 0.378 Ji Z[17] 2010 Hunan Chinese T2DM 427 WHO PCR-RFLP 0.830 Control 281 0.079 Li B[21] 2011 Yunan Chinese T2DM 232 WHO PCR-RFLP 0.260 Control 102 0.126 Lin HY[16] 2007 Taiwan Chinese T2DM 574 NA PCR-RFLP 0.193 Control 323 0.466 Fallah S[22] 2010 Tehran Irani T2DM 50 NA PCR-RFLP 0.493 Control 50 0.998 Hu RT[23] 2009 Va Chinese T2DM 96 WHO PCR-RFLP 0.487 Control 104 0.673 Hu RT[23] 2009 Lalu Chinese T2DM 54 WHO PCR-RFLP 0.088 Control 234 0.817 Pu LM[18] 2012 Beijing Chinese T2DM 270 WHO PCR-HRM 1.92 × 10-5 Control 282 0.086 Note. ADA: American Diabetes Association. WHO: World Health Organization. PCR-RFLP: Polymerase Chain Reaction-Restriction Fragment Length Polymorphism restriction fragment length polymorphism. NA: not reported in the paper. Table 2. Assessment of Case-control Studies Using Newcastle-Ottawa Scale for Evaluating Methodological Quality
Study Case Definition Representativeness of the Case Selection of Controls Definition of Controls Comparability Ascertainment of Exposure Same Method of Ascertainment for Cases and Controls Non-Response Rate Noso S 2007[15] √ √ √ √ √ √ √ √ Shimada T 2009[20] √ √ √ √ √ √ √ Shimada T 2009[20] √ √ √ √ √ √ √ Lin HY 2007[16] √ √ √ √ √ √ √ Ji Z 2010[17] √ √ √ √ √ √ Li B 2011[21] √ √ √ √ √ √ √ Hu RT 2009[23] √ √ √ √ √ √ √ Hu RT 2009[23] √ √ √ √ √ √ √ Pu LM 2012[18] √ √ √ √ √ √ √ √ Fallah S 2010[12] √ √ √ √ √ √ -
[1] Canivell S, Gomis R. Diagnosis and classification of autoimmune diabetes mellitus. Autoimmun Rev, 2014; 13, 403-7. doi: 10.1016/j.autrev.2014.01.020 [2] International Diabetes Federation. Annual Report 2013-2014. http://www.idf.org/regions/EUR/annualreports. [2016-12-26] [3] Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med, 2010; 362, 1090-101. doi: 10.1056/NEJMoa0908292 [4] Ashcroft FM, Rorsman P. Diabetes mellitus and the beta cell: the last ten years. Cell, 2012; 14, 1160-71. [5] Hivert MF, Vassy JL, Meigs JB. Susceptibility to type 2 diabetes mellitus-from genes to prevention. Nat Rev Endocrinol, 2014; 10, 198-205. doi: 10.1038/nrendo.2014.11 [6] Hanson RL, Muller YL, Kobes S, et al. A genome-wide association study in American Indians implicates DNER as a susceptibility locus for type 2 diabetes. Diabetes, 2014; 63, 369-76. doi: 10.2337/db13-0416 [7] Ahlqvist E, Ahluwalia TS, Groop L. Genetics of type 2 diabetes. Clin Chem, 2011, 57; 241-54. doi: 10.1373/clinchem.2010.157016 [8] Li H, Lindholm E, Almgren P, et al. Possible human leukocyte antigen-mediated genetic interaction between type 1 and type 2 Diabetes. J Clin Endocrinol Metab, 2001; 86, 574-82. https://www.researchgate.net/profile/Eero_Lindholm/publication/12171696_Possible_Human_Leukocyte_Antigen-Mediated_Genetic_Interaction_between_Type_1_and_Type_2_Diabetes_1/links/54ddb7180cf25b09b91484b1/Possible-Human-Leukocyte-Antigen-Mediated-Genetic-Interaction-between-Type-1-and-Type-2-Diabetes-1.pdf [9] Eftychi C, Howson JM, Barratt BJ, et al. Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. Diabetes, 2004; 53, 870-3. doi: 10.2337/diabetes.53.3.870 [10] Kroetz MB. SUMO: a ubiquitin-like protein modifier. Yale J Biol Med, 2005; 78, 197-201. http://europepmc.org/articles/PMC2259148?pdf=render [11] Guo D, Li M, Zhang Y, et al. A functional variant of SUMO4, a new Ⅰ kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet, 2004; 36, 837-41. doi: 10.1038/ng1391 [12] Tsurumaru M, Kawasaki E, Ida H, et al. Evidence for the role of small ubiquitin-like modifier 4 as a general autoimmunity locus in the Japanese population. J Clin Endocrinol Metab, 2006; 91, 3138-43. doi: 10.1210/jc.2006-0206 [13] Bohren KM, Nadkarni V, Song JH, et al. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type Ⅰ diabetes mellitus. J Biol Chem, 2004; 279, 27233-8. doi: 10.1074/jbc.M402273200 [14] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol, 2011; 11, 98-107. doi: 10.1038/nri2925 [15] Noso S, Fujisawa T, Kawabata Y, et al. Association of small ubiquitin-like modifier 4 (SUMO4) variant, located in IDDM5 locus, with type 2 diabetes in the Japanese population. J Clin Endocrinol Metab, 2007; 92, 2358-62. doi: 10.1210/jc.2007-0031 [16] Lin HY, Wang CL, Hsiao PJ, et al. SUMO4 M55V variant is associated with diabetic nephropathy in type 2 diabetes. Diabetes, 2007; 56, 1177-80. doi: 10.2337/db06-1283 [17] Ji Z, Dai Z, Xu Y. Association between small ubiquitin-like modifer 4 M55V polymorphism with type 2 diabetes and related factors. Chin J Diabetes Mellitus, 2010; 2, 344-8. (In Chinese) [18] Pu LM, Nan N, Yang ZN, et al. Association between SUMO4 polymorphisms and type 2 diabetes mellitus. Hereditas (Beijing), 2012; 3, 315-25. (In Chinese) [19] Sozen S, Horozoglu C, Bireller ES, et al. Association of SUMO4 M55V and-94ins/del gene variants with type-2 diabetes. In Vivo, 2014; 28, 919-23. http://iv.iiarjournals.org/content/28/5/919.full [20] Shimada T, Furukawa Y, Furuta H, et al. SUMO4 Met55Val polymorphism is associated with coronary heart disease in Japanese type 2 diabetes individuals. Diabetes Res Clin Pract, 2009; 85, 85-9. doi: 10.1016/j.diabres.2009.04.001 [21] Li B, Li HB, Wang YM, et al. The association of SUMO4 Gene 163 A/G polymorphism with type 2 diabetic nephropathy. Chin J Diabetes, 2011; 19, 726-8. (In Chinese) http://en.cnki.com.cn/Article_en/CJFDTOTAL-ZGTL201110004.htm [22] Fallah S, Jafarzadeh M, Hedayati M. No association of the SUMO4 polymorphism M55V variant in type 2 diabetes in Iranian subjects. Diabetes Res Clin Pract, 2010; 90, 191-5. doi: 10.1016/j.diabres.2010.05.033 [23] Hu RT, Song DP. The association of SUMO4 Gene 163 A/G polymorphism and dysglycemia in Va and Lalu population. Kunming Medical University, 2009. (In Chinese) [24] Tang ST, Peng WJ, Wang CJ, et al. Polymorphism M55V in gene encoding small ubiquitin-like modifier 4 (SUMO4) protein associates with susceptibility to type 1 (and type 2) diabetes. Diabetes Metab Res Rev, 2012; 28, 679-87. doi: 10.1002/dmrr.v28.8 [25] Meng QJ, Wang JS, Jiang J, et al. A meta-analysis on association between SUMO4 M55V polymorphism and type 2 diabetes mellitus. Chin J Diabetes, 2013; 21, 591-3. [26] Khodaeian M, Enayati S, Tabatabaei-Malazy O, et al. Association between Genetic Variants and Diabetes Mellitus in Iranian Populations: A Systematic Review of Observational Studies. J Diabetes Res, 2015; 2015, 585917. https://www.researchgate.net/publication/274631365_Association_between_Genetic_Variants_and_Diabetes_Mellitus_in_Iranian_Populations_A_Systematic_Review_of_Observational_Studies [27] Sale MM, Freedman BI, Langefeld CD, et al. A genome-wide scan for type 2 diabetes in African-American families reveals evidence for a locus on chromosome 6q. Diabetes, 2004; 53, 830-7. doi: 10.2337/diabetes.53.3.830 [28] Xiang K, Wang Y, Zheng T, et al. Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes, 2004; 53, 228-34. doi: 10.2337/diabetes.53.1.228 [29] Silander K, Scott LJ, Valle TT, et al. A large set of Finnish affected sibling pair families with type 2 diabetes suggests susceptibility loci on chromosomes 6, 11, and 14. Diabetes, 2004; 53, 821-9. doi: 10.2337/diabetes.53.3.821 [30] Song GG, Choi SJ, Ji JD, et al. Association between the SUMO4 M55V (A163G) polymorphism and susceptibility to type 1 diabetes: A meta-analysis. Human Immunology, 2012; 73, 1055-9. doi: 10.1016/j.humimm.2012.07.341 [31] Guo D, Li M, Zhang Y, et al. A functional variant of SUMO4, a new Ⅰ kappa B alpha modifier, is associated with type 1 diabetes. Nature Genetics, 2004; 36, 837-41. doi: 10.1038/ng1391 [32] Wang CY, Yang P, Li M, et al. Characterization of a negative feedback network between SUMO4 expression and NFkappaB transcriptional activity. Biochem Biophys Res Commun, 2009; 381, 477-81. doi: 10.1016/j.bbrc.2009.02.060 [33] Benzler J, Ganjam GK, Pretz D, et al. Central inhibition of IKKβ/NF-κB signaling attenuates high-fat diet-induced obesity and glucose intolerance. Diabetes, 2015; 64, 2015-27. doi: 10.2337/db14-0093 [34] Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med, 2005; 11, 183-90. doi: 10.1038/nm1166 [35] Cyphert TJ, Morris RT, House LM, et al. NF-κB-dependent airway inflammation triggers systemic insulin resistance. Am J Physiol Regul Integr Comp Physiol, 2015; 309, R1144-52. doi: 10.1152/ajpregu.00442.2014 [36] Liu Z, Dou W, Ni Z, et al. Deletion of Nrf2 leads to hepatic insulin resistance via the activation of NF-κB in mice fed a high-fat diet. Mol Med Rep, 2016; 1323-31. [37] Feng H, Su R, Song Y, et al. Positive Correlation between Enhanced Expression of TLR4/MyD88/NF-κB with Insulin Resistance in Placentae of Gestational Diabetes Mellitus. PLoS One, 2016; 11, e0157185. doi: 10.1371/journal.pone.0157185 [38] Ji Z, Dai Z, Huang Y, et al. Association of SUMO4 Met55Val variation with increased insulin resistance in newly diagnosed type 2 diabetes in a Chinese population. J Huazhong Univ Sci Technolog Med Sci, 2011; 31, 306-11. doi: 10.1007/s11596-011-0372-9